178
Participants
Start Date
November 21, 2016
Primary Completion Date
March 25, 2024
Study Completion Date
March 25, 2024
Magrolimab
Administered intravenously
Rituximab
Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
Gemcitabine
Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
Oxaliplatin
Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
Allopurinol
Administered orally during Cycle 1
St. Vincent's Hospital Melbourne, Melbourne
Princess Alexandra Hospital, Brisbane
Linear Clinical Research Ltd, Nedlands
Hospital of the University of Pennsylvania, Philadelphia
National Institutes of Health Clinical Center/ National Cancer Institute, Bethesda
Levine Cancer Institute, Charlotte
Georgia Cancer Center at Augusta University, Augusta
University of Alabama At Birmingham (Uab), Birmingham
The Sarah Cannon Research Institute, Nashville
University of Michigan, Ann Arbor
University of Minnesota Medical Center, Fairview, Minneapolis
University of Chicago Medical Center, Chicago
Washington University School of Medicine Siteman Cancer Center, St Louis
Stephenson Cancer Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
Stanford Cancer Center, Stanford
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
The Churchill Hospital, Oxford
Lead Sponsor
The Leukemia and Lymphoma Society
OTHER
Gilead Sciences
INDUSTRY